The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis

Autor: Eichenfield, LF, Silverberg, JI, Carrascosa, JM, Rubel, D, Watts, S, Casillas, M, DeLozier, AM, Pierce, E

Publikováno v: Journal of the American Academy of Dermatology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::97f8274c851b4a29ab1f8b6bec626d90
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3272

PSS31 - Mixed Methods Evaluation of An Itch Numeric Rating Scale Among Adult and Adolescent Patients With Atopic Dermatitis

Autor: Humphrey, L, Symonds, T, Gable, J, Abetz-Webb, L, Silverberg, JI, Griffiths, P, Eichenfield, LF, Wyrwich, KW, Paik, J, DeLozier, AM

Publikováno v: In Value in Health October-November 2017 20(9):A806-A806

Eradicating acne vulgaris of puberty: what makes for optimal therapy?

Autor: Silverberg NB, Silverberg JI, Silverberg AI

Publikováno v: Contemporary Pediatrics; Oct2005 Supplement, p12-22, 7p

Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis.

Autor: Silverberg JI; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Gooderham M; Queen's University, Kingston, Ontario, Canada.; SKiN Centre for Dermatology, Peterborough, Ontario, Canada., Katoh N; Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan., Aoki V; University of São Paulo School of Medicine, São Paulo, Brazil., Pink AE; St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust, London, UK., Binamer Y; Alfaisal University, Riyadh, Saudi Arabia.; King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia., Rademaker M; Waikato Clinical Campus, Auckland Medical School, Waikato, New Zealand., Fomina D; Moscow City Center of Allergy and Immunology, Clinical City Hospital 52, Moscow, Russia.; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; Astana Medical University, Astana, Kazakhstan., Gutermuth J; Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.; Vrije Universiteit Brussel (VUB), SKIN Research Group, Brussels, Belgium., Ahn J; National Medical Center, Seoul, South Korea., Valenzuela F; University of Chile, Santiago, Chile., Ameen M; Royal Free NHS Foundation Trust, London, UK., Steinhoff M; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.; College of Health and Life Sciences, Hamad-Bin Khalifa University-Qatar, Doha, Qatar.; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar., Kirchhof MG; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; The Ottawa Hospital, Ottawa, Ontario, Canada., Lio P; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Wollenberg A; Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Munich, Germany.; Department of Dermatology, Augsburg University Hospital, Augsburg, Germany.; Comprehensive Center for Inflammatory Medicine CCIM, University Hospital Schleswig-Holstein UKSH, Luebeck, Germany.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Nov; Vol. 38 (11), pp. 2139-2148. Date of Electronic Publication: 2024 Jul 11.

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

Autor: Silverberg JI; Department of Dermatology, George Washington University School of Medicine, Washington, DC, USA., Rosmarin D; Indiana University School of Medicine, Indianapolis, IN, USA., Chovatiya R; Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.; Center for Medical Dermatology + Immunology Research, Chicago, IL, USA., Bieber T; Department of Dermatology, University Hospital, Zürich, Switzerland.; Medicine Campus, Davos, Switzerland., Schleicher S; DermDox Centers for Dermatology, Sugarloaf, PA, USA., Beck L; University of Rochester Medical Center, Rochester, NY, USA., Gooderham M; Department of Medicine, Queen's University, Kingston, ON, Canada., Chaudhry S; Nektar Therapeutics, San Francisco, CA, USA., Fanton C; Nektar Therapeutics, San Francisco, CA, USA., Yu D; Nektar Therapeutics, San Francisco, CA, USA., Levy J; Levy Informatics LLC, Chapel Hill, NC, USA., Liu Y; Nektar Therapeutics, San Francisco, CA, USA., Miyazaki T; Nektar Therapeutics, San Francisco, CA, USA., Tagliaferri M; Nektar Therapeutics, San Francisco, CA, USA., Schmitz C; Eli Lilly and Company, Indianapolis, IN, USA., Nirula A; Recludix Pharma, San Diego, CA, USA, formerly affiliated with Eli Lilly and Company, Indianapolis, IN, USA., Kotzin B; Nektar Therapeutics, San Francisco, CA, USA., Zalevsky J; Nektar Therapeutics, San Francisco, CA, USA. JZalevsky@nektar.com.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 25; Vol. 15 (1), pp. 9230. Date of Electronic Publication: 2024 Oct 25.